ATE513855T1 - Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür - Google Patents
Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafürInfo
- Publication number
- ATE513855T1 ATE513855T1 AT06706157T AT06706157T ATE513855T1 AT E513855 T1 ATE513855 T1 AT E513855T1 AT 06706157 T AT06706157 T AT 06706157T AT 06706157 T AT06706157 T AT 06706157T AT E513855 T1 ATE513855 T1 AT E513855T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- receptor alpha
- receptor
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05000003 | 2005-01-03 | ||
EP05002229 | 2005-02-03 | ||
PCT/EP2006/000005 WO2006072564A1 (en) | 2005-01-03 | 2006-01-02 | Antibodies against il-13 receptor alpha 1 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE513855T1 true ATE513855T1 (de) | 2011-07-15 |
Family
ID=36199730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06706157T ATE513855T1 (de) | 2005-01-03 | 2006-01-02 | Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür |
Country Status (20)
Country | Link |
---|---|
US (2) | US7807158B2 (de) |
EP (1) | EP1836226B1 (de) |
JP (1) | JP5086098B2 (de) |
KR (1) | KR100934894B1 (de) |
AR (1) | AR051888A1 (de) |
AT (1) | ATE513855T1 (de) |
AU (1) | AU2006204480B2 (de) |
BR (1) | BRPI0606368A2 (de) |
CA (1) | CA2592614C (de) |
CR (1) | CR9209A (de) |
HK (1) | HK1112006A1 (de) |
IL (1) | IL184205A0 (de) |
MA (1) | MA29226B1 (de) |
MX (1) | MX2007008128A (de) |
NO (1) | NO20073655L (de) |
NZ (1) | NZ556126A (de) |
RU (1) | RU2413736C2 (de) |
SG (1) | SG172504A1 (de) |
TW (2) | TWI306862B (de) |
WO (1) | WO2006072564A1 (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
PL2769992T3 (pl) * | 2006-10-02 | 2021-08-02 | Regeneron Pharmaceuticals, Inc. | Przeciwciała ludzkie o wysokim powinowactwie względem ludzkiego receptora IL-4 |
JP2010507365A (ja) * | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | 抗IL−13Rα1抗体およびその使用 |
US8207304B2 (en) | 2006-10-19 | 2012-06-26 | Csl Limited | Antibody antagonists of interleukin-13 receptor α1 |
ES2658239T3 (es) * | 2006-10-19 | 2018-03-08 | Csl Limited | Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13 |
WO2008145351A1 (en) | 2007-06-01 | 2008-12-04 | F. Hoffmann-La Roche Ag | Immunoglobulin purification |
CN101687038A (zh) * | 2007-07-10 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 新型制剂 |
ES2695999T3 (es) | 2007-10-12 | 2019-01-11 | Hoffmann La Roche | Expresión de proteínas a partir de múltiples ácidos nucleicos |
EP2050764A1 (de) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Neues polyvalentes bispezifisches Antikörperformat und Verwendung |
US8227195B2 (en) | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
BRPI1006448B1 (pt) * | 2009-03-25 | 2021-08-17 | Genentech, Inc | Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3 |
US8530392B2 (en) * | 2009-05-13 | 2013-09-10 | Shionogi & Co., Ltd. | Test agent for visceral obesity and use thereof |
JP5813638B2 (ja) | 2009-07-30 | 2015-11-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 可動クロマトグラフィーカラムセパレータ |
PT2483305T (pt) | 2009-10-01 | 2016-11-04 | Hoffmann La Roche | Filtração final de imunoglobulina em várias etapas |
WO2011038894A1 (en) | 2009-10-01 | 2011-04-07 | F. Hoffmann-La Roche Ag | Protein a chromatography |
EP2491397B1 (de) | 2009-10-19 | 2017-04-19 | F. Hoffmann-La Roche AG | NICHT KREUZREAKTIVE ANTI-IgG-ANTIKÖRPER |
RU2567804C2 (ru) | 2009-12-22 | 2015-11-10 | Ф. Хоффманн-Ля Рош Аг | Агрегация, зависящая от последовательностей |
CA3043423A1 (en) | 2010-08-17 | 2012-02-23 | F. Hoffmann-La Roche Ag | Anti-human igg1 antibody |
EP2671074A1 (de) | 2011-02-02 | 2013-12-11 | F. Hoffmann-La Roche AG | Chromatographiesäulenunterstützung |
AU2012245205B2 (en) * | 2011-04-21 | 2017-06-01 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
PT3470432T (pt) | 2012-08-21 | 2021-12-14 | Regeneron Pharma | Métodos para tratamento ou prevenção da asma por meio de administração de um antagonista de il-4r |
TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
US10059771B2 (en) | 2013-06-21 | 2018-08-28 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an IL-4R antagonist |
MX363403B (es) | 2013-07-04 | 2019-03-22 | Hoffmann La Roche | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
TWI682781B (zh) | 2013-07-11 | 2020-01-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
BR112016014293B1 (pt) | 2013-12-20 | 2023-11-21 | Intervet International B.V | Região de fragmento cristalizável canino, anticorpo caninizado, e,composição farmacêutica |
KR102368450B1 (ko) | 2014-02-21 | 2022-02-28 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
MX2016011132A (es) | 2014-02-28 | 2016-12-08 | Regeneron Pharma | Métodos para tratar una infección cutánea mediante la administración de un antagonista de il-4r. |
RU2020117210A (ru) | 2014-09-30 | 2020-06-16 | Интервет Интернэшнл Б.В. | Антитела к pd-l1, связывающие pd-l1 собаки |
EP3218412A1 (de) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Verfahren zur behandlung von chronischer sinusitis mit nasenpolypen durch verabreichung eines il-4r-antagonisten |
JP7073253B2 (ja) * | 2015-08-21 | 2022-05-23 | エフ.ホフマン-ラ ロシュ アーゲー | アフィニティークロマトグラフィーにおける宿主細胞タンパク質の低減方法 |
BR112018001511A2 (pt) | 2015-08-21 | 2018-09-18 | Hoffmann La Roche | ?uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpo de isótipo igg1 ou igg4 humano |
US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
WO2018011405A1 (en) * | 2016-07-15 | 2018-01-18 | Universität Zürich | Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
US10485844B2 (en) | 2016-09-22 | 2019-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor |
TW202332696A (zh) | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
CN111526920A (zh) | 2017-10-30 | 2020-08-11 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂来治疗或预防哮喘的方法 |
US11292850B2 (en) | 2018-03-21 | 2022-04-05 | ALX Oncology Inc. | Antibodies against signal-regulatory protein α and methods of use |
MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
CA3132587A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
US20210277131A1 (en) | 2019-03-26 | 2021-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF |
CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2022186772A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
WO2022186773A1 (en) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION |
WO2023048651A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Method for treatment of moderate to severe atoptic dematitis |
WO2023048650A1 (en) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF |
TW202333784A (zh) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體調配物 |
WO2024043837A1 (en) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | High concentration anti-il13r antibody formulation |
WO2024054157A1 (en) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5614191A (en) | 1995-03-15 | 1997-03-25 | The United States Of America As Represented By The Department Of Health And Human Services | IL-13 receptor specific chimeric proteins and uses thereof |
DE69638050D1 (de) | 1995-10-23 | 2009-11-19 | Zenyth Operations Pty Ltd | Hemopoietin-rezeptor und dafür kodierende genetische sequenzen |
US5843659A (en) * | 1996-03-21 | 1998-12-01 | Apoptosis Technology, Inc. | Apoptosis gene EI24, compositions, and methods of use |
CA2468950A1 (en) * | 2001-11-27 | 2003-06-05 | Mochida Pharmaceutical Co., Ltd. | Anti-il13 receptor .alpha.1 neutralizing antibody |
AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
CA2480059C (en) * | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
CA2518956A1 (en) * | 2003-03-10 | 2004-09-23 | Applera Corporation | Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof |
EP2364728A1 (de) * | 2003-07-15 | 2011-09-14 | Amgen, Inc | Menschliche Anti-NGF-neutralisierende Antikörper als selektive NGF-Pfadhemmer |
-
2005
- 2005-12-30 TW TW094147847A patent/TWI306862B/zh not_active IP Right Cessation
- 2005-12-30 TW TW097137970A patent/TW200902555A/zh unknown
-
2006
- 2006-01-02 CA CA2592614A patent/CA2592614C/en not_active Expired - Fee Related
- 2006-01-02 KR KR1020077015296A patent/KR100934894B1/ko not_active IP Right Cessation
- 2006-01-02 JP JP2007548835A patent/JP5086098B2/ja not_active Expired - Fee Related
- 2006-01-02 AU AU2006204480A patent/AU2006204480B2/en not_active Expired - Fee Related
- 2006-01-02 WO PCT/EP2006/000005 patent/WO2006072564A1/en active Application Filing
- 2006-01-02 SG SG2009087206A patent/SG172504A1/en unknown
- 2006-01-02 AT AT06706157T patent/ATE513855T1/de not_active IP Right Cessation
- 2006-01-02 BR BRPI0606368-3A patent/BRPI0606368A2/pt not_active IP Right Cessation
- 2006-01-02 MX MX2007008128A patent/MX2007008128A/es active IP Right Grant
- 2006-01-02 RU RU2007129676/10A patent/RU2413736C2/ru not_active IP Right Cessation
- 2006-01-02 NZ NZ556126A patent/NZ556126A/en not_active IP Right Cessation
- 2006-01-02 EP EP06706157A patent/EP1836226B1/de active Active
- 2006-01-03 US US11/325,197 patent/US7807158B2/en not_active Expired - Fee Related
- 2006-01-03 AR ARP060100010A patent/AR051888A1/es unknown
-
2007
- 2007-06-25 IL IL184205A patent/IL184205A0/en unknown
- 2007-06-26 CR CR9209A patent/CR9209A/es not_active Application Discontinuation
- 2007-07-06 MA MA30048A patent/MA29226B1/fr unknown
- 2007-07-17 NO NO20073655A patent/NO20073655L/no not_active Application Discontinuation
-
2008
- 2008-06-23 HK HK08106940.0A patent/HK1112006A1/xx not_active IP Right Cessation
-
2010
- 2010-07-26 US US12/843,225 patent/US20110086026A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR100934894B1 (ko) | 2010-01-07 |
TW200635945A (en) | 2006-10-16 |
RU2413736C2 (ru) | 2011-03-10 |
CR9209A (es) | 2007-08-28 |
WO2006072564A1 (en) | 2006-07-13 |
EP1836226B1 (de) | 2011-06-22 |
TWI306862B (en) | 2009-03-01 |
RU2007129676A (ru) | 2009-02-10 |
NZ556126A (en) | 2008-09-26 |
JP5086098B2 (ja) | 2012-11-28 |
US7807158B2 (en) | 2010-10-05 |
IL184205A0 (en) | 2007-10-31 |
MX2007008128A (es) | 2007-07-20 |
TW200902555A (en) | 2009-01-16 |
KR20070091180A (ko) | 2007-09-07 |
US20110086026A1 (en) | 2011-04-14 |
CA2592614A1 (en) | 2006-07-13 |
SG172504A1 (en) | 2011-07-28 |
MA29226B1 (fr) | 2008-02-01 |
AR051888A1 (es) | 2007-02-14 |
JP2008526187A (ja) | 2008-07-24 |
BRPI0606368A2 (pt) | 2009-06-23 |
HK1112006A1 (en) | 2008-08-22 |
AU2006204480A1 (en) | 2006-07-13 |
AU2006204480B2 (en) | 2011-06-09 |
CA2592614C (en) | 2015-04-14 |
NO20073655L (no) | 2007-08-02 |
US20060263356A1 (en) | 2006-11-23 |
EP1836226A1 (de) | 2007-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE513855T1 (de) | Antikörper gegen il-13-rezeptor-alpha-1 und verwendungen dafür | |
LTPA2020523I1 (lt) | Anti-CD79b antikūnai ir imunokonjugatai ir jų panaudojimo būdai | |
ATE523524T1 (de) | Antikörper und immunkonjugate gegen tat226 | |
NO20082454L (no) | Anti-alfa2 integrin antistoffer og deres anvendelser | |
DK2222706T3 (da) | Antibodies against human nkg2d and uses thereof | |
ATE456581T1 (de) | Antikörper gegen il21-rezeptor und deren verwendung | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
ATE501174T1 (de) | Antikörper gegen madcam | |
DE602005023639D1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
ATE550355T1 (de) | Antikörper gegen ccr5 und ihre verwendung | |
DK2059535T3 (da) | Prlr-specifikt antistof og anvendelser deraf | |
DK2209806T3 (da) | Anti-hepcidin-antistoffer og anvendelser deraf | |
BRPI0820298A2 (pt) | anticorpos anti-vegf composições e métodos | |
IL195658A0 (en) | Anti-nkg2a antibodies and uses thereof | |
DE602007009443D1 (de) | Nanodrahtzusammensetzung und Herstellungsverfahren dafür | |
DE602007010795D1 (de) | Blattsauger und -häcksler | |
CY2013046I2 (el) | Καινοτομος χρηση των αντισωματων αντι il-1bhta | |
ATE511507T1 (de) | Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten | |
EP2094730A4 (de) | Verfahren und materialien in zusammenhang mit anti-amyloid-antikörpern | |
ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
DE502007001209D1 (de) | Wachszusammensetzung und deren Verwendung | |
DE602007000247D1 (de) | Variabeler Schwungradmechanismus und Schwungradanordnung | |
DE602007006540D1 (de) | Cyclopropancarboxylate und deren verwendung als pestizide | |
BRPI0816689A2 (pt) | antígenos mutantes gas57 e anticorpos gas57 | |
DE602006002933D1 (de) | Verbund-Materialien und Herstellungsmethoden |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |